Cancer treatment and survivorship statistics, 2014

CA Cancer Journal for Clinicians

Volumn 64, Issue 4, 2014, Pages 252-271

  Desantis, Carol E ^a   Lin, Chun Chieh ^a   Mariotto, Angela B ^b   Siegel, Rebecca L ^a   Stein, Kevin D ^c   Kramer, Joan L ^a   Alteri, Rick ^a   Robbins, Anthony S ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BEHAVIORAL RESEARCH CENTER   (United States)

Author keywords

cancer; prevalence; statistics; survivorship; treatment patterns

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; HODGKIN DISEASE; HUMAN; LUNG CANCER; MELANOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; THYROID CANCER; UNITED STATES; UTERUS CANCER;

CANCER; PREVALENCE; STATISTICS; SURVIVORSHIP; TREATMENT PATTERNS;

FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; NEOPLASMS; PREVALENCE; SEER PROGRAM; SURVIVORS; UNITED STATES;

EID: 84904155440     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21235     Document Type: Article

References (107)

1. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120: 1290-1314.
2. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012; 21: 2108-2117.
3. Verdecchia A, De Angelis G, Capocaccia R,. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002; 21: 3511-3526. (Pubitemid 35314665)
4. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD: National Cancer Institute; 2012.
5. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M,. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control. 2006; 17: 1215-1226. (Pubitemid 44772821)
6. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML,. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
7. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.
8. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
9. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2012 Sub (1973-2010 varying)-Linked To County Attributes-Total US, 1969-2011 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2013, based on the November 2012 submission.
10. Surveillance Research Program. National Cancer Institute SEER Stat software. Version 8.1.2. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2013.
11. American College of Surgeons Commission on Cancer. National Cancer Data Base 2011 Data Submission. Chicago, IL: American College of Surgeons; 2013.
12. Lerro CC, Robbins AS, Phillips JL, Stewart AK,. Comparison of cases captured in the National Cancer Data Base with those in population-based central cancer registries. Ann Surg Oncol. 2013; 20: 1759-1765.
13. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY,. Comparison of Commission on Cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27: 4177-4181.
14. Fedewa SA, Ward EM, Stewart AK, Edge SB,. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010; 28: 4135-4141.
15. Bhargava A, Du XL,. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009; 115: 2999-3008.
16. Surveillance, Epidemiology, and End Results (SEER) Program. SEER-Medicare linked database 2006-2010. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program, Health Services and Economics Branch; 2013.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2014; 2014.
18. Jatoi I, Proschan MA,. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005; 28: 289-294. (Pubitemid 40800482)
19. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009; 16: 2682-2690.
20. Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K,. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg. 2011; 127: 18-26.
21. Jagsi R, Jiang J, Momoh AO, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol. 2014; 32: 919-926.
22. Brennan ME, Spillane AJ,. Uptake and predictors of post-mastectomy reconstruction in women with breast malignancy-systematic review. Eur J Surg Oncol. 2013; 39: 527-541.
23. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792. (Pubitemid 41549890)
24. Vona-Davis L, Rose DP,. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009; 18: 883-893.
25. Danforth Jr DN Jr,. Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res. 2013; 15: 208.
26. Curtis E, Quale C, Haggstrom D, Smith-Bindman R,. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008; 112: 171-180.
27. DiSipio T, Rye S, Newman B, Hayes S,. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013; 14: 500-515.
28. Lawenda BD, Mondry TE, Johnstone PA,. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009; 59: 8-24.
29. Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 2010; 304: 2699-2705.
30. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H,. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009; 302: 1985-1992.
31. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH,. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008; 99: 604-610.
32. Kehlet H, Jensen TS, Woolf CJ,. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006; 367: 1618-1625. (Pubitemid 43674227)
33. Steegers MA, Wolters B, Evers AW, Strobbe L, Wilder-Smith OH,. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J Pain. 2008; 9: 813-822.
34. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL,. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012; 104: 386-405.
35. Conte P, Frassoldati A,. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J. 2007; 13: 28-35. (Pubitemid 46046490)
36. Pinto AC, de Azambuja E,. Improving quality of life after breast cancer: dealing with symptoms. Maturitas. 2011; 70: 343-348.
37. Ward E, Desantis C, Robbins A, Kohler B, Jemal A,. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 83-103.
38. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309: 2371-2381.
39. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27: 2356-2362.
40. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH,. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011; 29: 4045-4053.
41. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780. (Pubitemid 46606434)
42. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M,; Swedish Adult Acute Lymphocytic Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006; 107: 1551-1561. (Pubitemid 44546916)
43. Bleyer A,. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007; 57: 242-255. (Pubitemid 47312083)
44. Albritton K, Barr R, Bleyer A,. The adolescence of young adult oncology. Semin Oncol. 2009; 36: 478-488.
45. Siegel R, DeSantis C, Jemal A,. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-117.
46. Jansen L, Koch L, Brenner H, Arndt V,. Quality of life among long-term (≥5 years) colorectal cancer survivors-systematic review. Eur J Cancer. 2010; 46: 2879-2888.
47. Aghili M, Izadi S, Madani H, Mortazavi H,. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol. 2010; 6: 35-41.
48. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ,. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007; 16: 566-571. (Pubitemid 46548662)
49. National Cancer Institute. PDQ® Adult Acute Myeloid Leukemia Treatment. Bethesda, MD: National Cancer Institute; 2013. cancer.gov/ cancertopics/pdq/treatment/adultAML/healthprofessional. Accessed January 6, 2014.
50. Faderl S, Jeha S, Kantarjian HM,. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 1337-1354. (Pubitemid 37151487)
51. Moorman AV, Harrison CJ, Buck GA, et al. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109: 3189-3197. (Pubitemid 46572503)
52. Inaba H, Greaves M, Mullighan CG,. Acute lymphoblastic leukaemia. Lancet. 2013; 381: 1943-1955.
53. Bhatia S,. Disparities in cancer outcomes: lessons learned from children with cancer. Pediatr Blood Cancer. 2011; 56: 994-1002.
54. Jain P, O'Brien S,. Richter's transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012; 26: 1146-1152.
55. Surveillance, Epidemiology and End Results (SEER) Program. SEER Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2010, Custom File With County, ACS Facts and Figures Projection Project. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2013.
56. Tsai HK, Mauch PM,. Nodular lymphocyte-predominant hodgkin lymphoma. Semin Radiat Oncol. 2007; 17: 184-189. (Pubitemid 46963029)
57. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339: 21-26. (Pubitemid 28304493)
58. Coiffier B,. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005; 23: 6387-6393. (Pubitemid 46218851)
59. Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A. 2002; 99: 8886-8891. (Pubitemid 34693653)
60. Costa LJ, Xavier AC, Wahlquist AE, Hill EG,. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013; 121: 4861-4866.
61. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321: 136-142. (Pubitemid 19180676)
62. Pui CH, Howard SC,. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008; 9: 257-268. (Pubitemid 351722945)
63. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63: 107-117.
64. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC Cancer. 2012; 12: 184.
65. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
66. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954. (Pubitemid 34716871)
67. Jang S, Atkins MB,. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013; 14: e60-e69.
68. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL,. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol. 2011; 65 (5 suppl 1): S69-S77.
69. Birkhahn M, Penson DF, Cai J, et al. Long-term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy. BJU Int. 2011; 108: 660-664.
70. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014; 15: 223-231.
71. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011; 117: 1429-1437.
72. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 2095-2101. (Pubitemid 40617061)
73. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
74. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009; 27: 4980-4985.
75. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
76. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368: 138-148.
77. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
78. Hoffman-Censits J, Kelly WK,. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19: 1335-1339.
79. Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014; 20: 9-14.
80. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436-445.
81. Grossmann M, Zajac JD,. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012; 14: 187-192.
82. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009; 27: 3452-3458.
83. Saylor PJ, Smith MR,. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013; 189 (suppl 1): S34-S42; discussion S43-S44.
84. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102: 39-46.
85. Wadhwa VK, Weston R, Mistry R, Parr NJ,. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009; 104: 800-805.
86. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011; 306: 2359-2366.
87. Levine GN, D'Amico AV, Berger P, et al. American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010; 60: 194-201.
88. Leung E, Warde P, Jewett M, et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int. 2013; 112: 1088-1095.
89. Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013; 109: 60-67.
90. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R,. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 965212.
91. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ,. Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306: 721-728.
92. Patel SS, Goldfarb M,. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. J Surg Oncol. 2013; 107: 665-672.
93. National Cancer Institute. Thyroid cancer treatment (PDQ®). cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional. Accessed January 23, 2014.
94. Santoro M, Carlomagno F,. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013; 5: a009233.
95. Nieder AM, Mackinnon JA, Huang Y, Fleming LE, Koniaris LG, Lee DJ,. Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. J Urol. 2008; 179: 491-495; discussion 495.
96. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS,. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013; 11: 13.
97. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012; 61: 705-711.
98. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013; 14: 863-872.
99. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 1083-1086. (Pubitemid 14207227)
100. Lutzeyer W, Rubben H, Dahm H,. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982; 127: 250-252. (Pubitemid 12131747)
101. Roghmann F, Becker A, Trinh QD, et al. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: a contemporary US-population-based cohort. Can Urol Assoc J. 2013; 7: E552-E560.
102. Polednak AP,. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev. 2008; 32: 190-199.
103. Arem H, Park Y, Pelser C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013; 105: 342-349.
104. Audette C, Waterman J,. The sexual health of women after gynecologic malignancy. J Midwifery Womens Health. 2010; 55: 357-362.
105. Tada H, Teramukai S, Fukushima M, Sasaki H,. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer. 2009; 9: 47.
106. American College of Surgeons. Cancer program standards 2012: ensuring patient-centered care. Version 1.2.1. facs.org/cancer/coc/programstandards2012. pdf. Accessed April 9, 2014.
107. Alliance for Quality Psychosocial Cancer Care. A recource guide for CoC-accredited facilities: meeting the Commission on Cancer patient-centered standards. cfah.org/pdfs/Alliance-Resource-Guide-3-2014.pdf. Accessed April 9, 2014.